INTRODUCTION {#s1}
============

The chromosome 5p15.33 *TERT-CLPTM1L* region has been repeatedly proved to be a susceptibility locus of multiple malignancies according to genome-wide association studies (GWAS). Independent susceptibility single nucleotide polymorphisms (SNPs) in this region were identified in lung cancer \[[@R1]--[@R5]\], melanoma \[[@R6]\], nonmelanoma skin cancer \[[@R7],[@R8]\], glioma \[[@R9]\], bladder cancer \[[@R10]\], pancreatic cancer \[[@R11]\], testicular germ cell cancer \[[@R12]\], estrogen-negative breast cancer \[[@R13]\], ovarian cancer \[[@R14]\] and prostate cancer \[[@R15]\], suggesting that the region harbors several essential elements associating etiology of multiple cancers. The chromosome 5p15.33 region harbors two plausible candidate coding genes *TERT* and *CLPTM1L*. *TERT* encodes the catalytic subunit of telomerase reverse transcriptase \[[@R16]\]. Activated *TERT* transcription in many cancers leads to increased telomerase activity to counteract telomere shortening and promotes malignant transformation of normal cells \[[@R17]\]. *CLPTM1L* encodes the cleft lip and palate-associated transmembrane 1 like protein (also known as cisplatin resistance related protein, *CRR9*). Accumulated evidences demonstrated that CLPTM1L may act as an oncogene in lung and pancreatic cancers \[[@R20]--[@R22]\].

As one of the most common and fatal malignant tumors in the world, esophageal squamous cell carcinoma (ESCC) was diagnosed at a relatively high frequency in China \[[@R24]\]. It has been shown that heavy alcohol drinking, tobacco smoking, micronutrient deficiency and dietary carcinogen exposure are risk factors of this lethal disease \[[@R25],[@R26]\]. However, only a portion of exposed individuals develop ESCC, indicating that genetic factors may also impact esophageal malignant transformation. Considering the involvement of the 5p15.33 *TERT-CLPTM1L* locus in ESCC is still largely unclear, we examined the associations between 15 haplotype-tagging SNPs (htSNP) across the *TERT-CLPTM1L* locus and ESCC risk in three large independent hospital-based case-control studies. To investigate the biological function of three ESCC susceptibility SNPs, we examined impacts of these genotypes on *TERT* or *CLPTM1L* expression using luciferase reporter gene assays and inspected the association between these polymorphisms and gene expression in esophageal tissues.

RESULTS {#s2}
=======

Associations between the TERT-CLPTM1L htSNPs and ESCC risk in the discovery case-control set {#s2_1}
--------------------------------------------------------------------------------------------

Genotype distributions of fifteen *TERT-CLPTM1L* genetic variants in the Jiangsu discovery set are showed in Table [1](#T1){ref-type="table"}. All observed genotype frequencies in either controls or cases conform to Hardy-Weinberg equilibrium (all *P* \> 0.05). Distributions of the all genotypes were then compared among patients and controls. Frequencies of rs2853691, rs2736100 or rs45136 genotypes among patients differed significantly from those among controls (all *P* \< 0.05). Logistic regression analyses revealed that rs2853691, rs2736100 and rs451360 SNPs were significantly associated with ESCC risk (rs2853691: allelic OR = 1.50, 95% CI = 1.25-1.80, *P* = 7.0 × 10^−6^; rs2736100: allelic OR = 1.39, 95% CI = 1.17-1.64, *P* = 7.8 × 10^−5^; rs45136: allelic OR = 0.69, 95% CI = 0.52-0.91, *P* = 0.007) (Table [1](#T1){ref-type="table"}). However, no statistically significant differences of other htSNPs were observed between cases and controls (all *P* \> 0.05) (Table [1](#T1){ref-type="table"}). Therefore, no additional genotyping and analyses on these twelve htSNPs were done in the next studies.

###### Associations between candidate SNPs in the *TERT-CLPTM1L* locus and risk of ESCC in Jiangsu case-control set

  No.      rs ID           Position      Base change   MAF[^1^](#tfn_001){ref-type="table-fn"}   Genotype (588 cases and 600 controls)   *P*^3^                                                 
  -------- --------------- ------------- ------------- ----------------------------------------- --------------------------------------- --------------- --------------- ---------------------- ------------------
  **1**    **rs2853691**   **1305950**   **T\>C**      **0.257**                                 **44.2/54.6**                           **43.5/39.4**   **12.3/6.0**    **1.50 (1.25-1.80)**   **7.0 × 10^−6^**
  2        rs2736122       1310621       G\>A          0.058                                     87.8/89.1                               12.1/10.3       0.1/0.6         1.07 (0.75-1.52)       0.701
  3        rs2075786       1319310       A\>G          0.128                                     74.5/76.3                               24.0/21.8       1.5/1.9         1.06 (0.83-1.36)       0.621
  4        rs4246742       1320356       T\>A          0.355                                     43.8/40.9                               44.6/47.0       11.7/12.0       0.93 (0.78-1.10)       0.397
  5        rs4975605       1328528       C\>A          0.053                                     90.5/89.7                               9.3/10.1        0.1/0.2         0.90 (0.61-1.33)       0.586
  **6**    **rs2736100**   **1339516**   **A\>C**      **0.405**                                 **28.1/35.7**                           **46.7/47.6**   **25.2/16.7**   **1.39 (1.17-1.64)**   **7.8 × 10^−5^**
  7        rs2853676       1341547       C\>T          0.126                                     75.3/75.9                               23.0/22.9       1.7/1.1         1.05 (0.82-1.35)       0.664
  8        rs2736098       1347086       C\>T          0.392                                     40.8/41.0                               39.7/39.6       19.5/19.4       1.01 (0.85-1.19)       0.919
  9        rs2853668       1353025       G\>T          0.293                                     49.5/49.8                               42.1/42.0       8.4/8.3         0.99 (0.83-1.19)       0.927
  10       rs2735845       1353584       C\>G          0.328                                     45.2/45.3                               44.5/43.7       10.3/11.0       0.99 (0.83-1.18)       0.890
  11       rs6554759       1370102       A\>G          0.045                                     90.3/91.1                               9.4/8.7         0.3/0.2         1.12 (0.76-1.66)       0.554
  **12**   **rs451360**    **1372680**   **C\>A**      **0.117**                                 **83.9/78.2**                           **15.3/20.2**   **0.8/1.6**     **0.69 (0.52-0.91)**   **0.007**
  13       rs380286        1373247       G\>A          0.125                                     77.4/76.5                               21.5/22.0       1.1/1.5         0.94 (0.73-1.21)       0.612
  14       rs402710        1373722       C\>T          0.325                                     44.5/45.8                               44.9/43.4       10.6/10.8       1.03 (0.86-1.22)       0.764
  15       rs452932        1383253       T\>C          0.160                                     72.6/70.9                               25.6/26.1       1.8/2.9         0.90 (0.71-1.13)       0.352

Note: ESCC, esophageal squamous cell carcinoma; MAF, minor allele frequency; OR, odds ratios; 95%CI, 95% confident intervals.

MAF in healthy controls.

\% of case/% of control.

Allelic OR calculated by logistic regression.

TERT-CLPTM1L rs2853691, rs2736100 and rs45136 polymorphisms contribute to ESCC susceptibility {#s2_2}
---------------------------------------------------------------------------------------------

Associations between genotypes of rs2853691, rs2736100 and rs45136 genetic variants and ESCC risk were calculated using unconditional logistic regression analyses in Jiangsu set (Table [2](#T2){ref-type="table"}). The rs2853691 G allele was showed to be risk allele; subjects having the AG or GG genotype had an OR of 1.19(95% CI = 0.88-1.60, *P* = 0.214) or 1.40(95% CI = 1.10-1.77, *P* = 0.006) for developing ESCC, respectively, compared with subjects having the AA genotype. It was observed that the odds of having the rs2736100 TG or GG genotype in patients was 1.32 (95% CI = 0.98-1.76, *P* = 0.066) or 1.37 (95% CI = 1.14-1.64, *P* = 7.3 × 10^−4^) compared with the TT genotype. Moreover, a significantly decreased OR was associated with the rs451360 GT genotype (OR = 0.67, 95% CI = 0.48-0.93, *P* = 0.018) but not the TT genotype (OR = 0.72, 95% CI = 0.41-1.29, *P* = 0.275). All ORs were adjusted for sex, age, smoking and alcohol drinking status.

###### Genotype frequencies of rs2853691 A\>G, rs2736100 T\>G and rs451360 G\>T SNPs in the *TERT-CLPTM1L* locus among cases and controls and their association with ESCC risk

  Studies        rs2853691 A\>G   rs2736100 T\>G                                                                                                  
  -------------- ---------------- ---------------- ------------ ----------------- -------------- ---- ------------ ------------ ----------------- --------------
                                  *n* = 588        *n* = 600                                          *n* = 588    *n* = 600                      
  Jiangsu set    AA               260(44.2)        328(54.6)    1.00                             TT   165(28.1)    214(35.7)    1.00              
                 AG               256(43.5)        236(39.4)    1.19(0.88-1.60)   0.214          TG   275(46.7)    285(47.6)    1.32(0.98-1.76)   0.066
                 GG               72(12.3)         36(6.0)      1.40(1.10-1.77)   0.006          GG   148(25.2)    101(16.7)    1.37(1.14-1.64)   7.3 × 10^−4^
                                  *n* = 1000       *n* = 1000                                         *n* = 1000   *n* = 1000                     
  Shandong set   AA               503(50.3)        557(55.7)    1.00                             TT   279(27.9)    363(36.3)    1.00              
                 AG               418(41.8)        393(39.3)    1.17(0.96-1.43)   0.116          TG   472(47.2)    475(47.5)    1.24(0.99-1.54)   0.051
                 GG               79(7.9)          50(5.0)      1.30(1.07-1.59)   0.010          GG   249(24.9)    162(16.2)    1.48(1.29-1.70)   2.2 × 10^−6^
                                  *n* = 510        *n* = 550                                          *n* = 508    *n* = 547                      
  Hebei set      AA               270(52.9)        315(57.3)    1.00                             TT   163(32.1)    222(40.6)    1.00              
                 AG               194(38.0)        202(36.7)    1.08(0.83-1.41)   0.584          TG   244(48.0)    241(44.0)    1.45(1.09-1.92)   0.011
                 GG               46(9.1)          33(6.0)      1.29(1.01-1.64)   0.048          GG   101(19.9)    84(15.4)     1.32(1.10-1.59)   3.2 × 10^−4^
                                  *n* = 2098       *n* = 2150                                         *n* = 2096   *n* = 2147                     
  Pooled         AA               1033(49.2)       1200(55.8)   1.00                             TT   607(29.0)    799(37.2)    1.00              
                 AG               868(41.4)        831(38.7)    1.16(1.01-1.32)   0.036          TG   991(47.2)    1001(46.6)   1.32(1.44-1.53)   2.1 × 10^−4^
                 GG               197(9.4)         119(5.5)     1.32(1.16-1.50)   2.2 × 10^−5^   GG   498(23.8)    347(16.2)    1.41(1.29-1.55)   4.0 × 10^−8^

  Studies        rs451360 G\>T                                               
  -------------- --------------- ------------ ------------ ----------------- --------------
                                 *n* = 588    *n* = 600                      
  Jiangsu set    GG              493(83.9)    469(78.2)    1.00              
                 GT              90(15.3)     121(20.2)    0.67(0.48-0.93)   0.018
                 TT              5(0.8)       10(1.6)      0.72(0.41-1.29)   0.275
                                 *n* = 1000   *n* = 1000                     
  Shandong set   GG              819(81.9)    760(76.0)    1.00              
                 GT              176(17.6)    222(22.2)    0.70(0.55-0.89)   0.003
                 TT              5(0.5)       18(1.8)      0.56(0.33-0.95)   0.033
                                 *n* = 510    *n* = 550                      
  Hebei set      GG              416(81.6)    417(75.8)    1.00              
                 GT              90(17.6)     124(22.6)    0.68(0.49-0.93)   0.017
                 TT              4(0.8)       9(1.6)       0.59(032-1.08)    0.086
                                 *n* = 2098   *n* = 2150                     
  Pooled         GG              1728(82.3)   1646(76.6)   1.00              
                 GT              356(17.0)    467(21.7)    0.68(0.58-0.81)   6.3 × 10^−6^
                 TT              14(0.7)      37(1.7)      0.61(0.44-0.85)   0.003

Note: ESCC, esophageal squamous cell carcinoma; OR, odds ratio; CI, confidence interval.

Data were calculated by logistic regression with adjustment for age, sex, smoking and drinking status.

In two validation sets (Shandong set and Hebei set), the significant associations between rs2853691, rs2736100 and rs45136 SNPs and ESCC risk were also observed (Table [2](#T2){ref-type="table"}). Individuals with rs2853691 GG genotype showed significantly increased ESCC risk compared with those with rs2853691 AA genotype in both validation sets (OR~Shandong~ = 1.30, 95% CI = 1.07-1.59, *P* = 0.010; OR~Hebei~ = 1.29, 95% CI = 1.01-1.64, *P* = 0.048). Carriers of rs2736100 GG genotype showed significantly elevated risks developing ESCC compared with rs2736100 TT carriers (OR~Beijing~ = 1.48, 95% CI = 1.29-1.70, *P* = 2.2 × 10^−6^; OR~Hebei~ = 1.32, 95% CI = 1.10-1.59, *P* = 3.2 × 10^−4^). The odds of having the rs451360 GT or TT genotype in patients was 0.70 (95% CI = 0.55-0.89, *P*=0.003) or 0.56 (95% CI = 0.33-0.95, *P* = 0.033) compared with the AA genotype in Shandong set. However, only rs451360 GT genotype was significantly associated with ESCC risk (OR = 0.68, 95% CI = 0.49-0.93, *P* = 0.017) in Hebei validation set.

In the pooled analyses, we found that the rs2853691 AG or GG genotype carriers had a 1.16-fold or 1.32-fold increased risk to develop ESCC compared to the AA genotype carriers (95% CI = 1.01-1.32, *P* = 0.036 or 95% CI = 1.16-1.50, *P* = 2.2 × 10^−5^) (Table [2](#T2){ref-type="table"}). Intriguingly, either rs2736100 TG or GG genotype was significantly associated with ESCC risk (OR = 1.32, 95% CI = 1.44-1.53, *P* = 2.1 × 10^−4^; OR = 1.41, 95% CI = 1.29-1.55, *P* = 4.0 × 10^−8^) compared to the TT genotype. Similarly, subjects having the rs451360 GT or TT genotype had an OR of 0.68 (95%CI = 0.58-0.81, *P* = 6.3 × 10^−6^) or 0.61 (95%CI = 0.44-0.85, *P* = 0.003) for developing ESCC compared with individual having the GG genotype.

Stratified analyses of associations between rs2853691, rs2736100 or rs451360 SNP and ESCC risk {#s2_3}
----------------------------------------------------------------------------------------------

The risk of ESCC associated with the rs2853691, rs2736100 or rs451360 SNP was further investigated by stratifying for age, sex, smoking and alcohol drinking status using the combined data of three case-control sets (Table [3](#T3){ref-type="table"}). For rs2853691, a significantly increased risk of ESCC associated with the rs2853691 GG genotype compared with the AA genotype was observed for both groups stratified by sex, smoking and drinking status (all *P* \< 0.05) or the group aged 58 years or younger (*P* = 5.4 × 10^−5^). Additionally, the rs2853691 AG genotype was only associated with ESCC risk in the male group (*P* = 0.026), the smoking group (*P* = 0.008) or the drinking group (*P* = 0.013). For rs2736100, significant associations between TG or GG genotype and ESCC risk were observed in all stratified groups (all *P* \< 0.05), but not in the drinking group (*P* = 0.974). There was a significantly multiplicative gene-drinking interaction (*P*~interaction~ = 0.012). For rs451360, the TT genotype was only associated with ESCC risk in the male group (*P* = 0.006), the group aged 58 years or younger (*P* = 0.016), the non-smoking group (*P* = 0.025) or the drinking group (*P* = 0.005). However, significant associations between the rs451360 GT genotype and ESCC risk were observed in all stratified groups (all *P* \< 0.05), but not in the female group (*P* = 0.326).

###### Risk of ESCC associated with rs2853691 A\>G, rs2736100 T\>G and rs451360 G\>T genotypes by age, sex, smoking, and drinking status

  Variable     rs2853691 A\>G                                                                               
  ------------ ---------------- --------- ----------------- ------- -------- ----------------- ------------ -------
  Sex                                                                                                       0.842
   Male        789/918          661/624   1.19(1.02-1.38)   0.026   137/93   1.27(1.10-1.47)   0.001        
   Female      244/288          207/207   0.88(0.62-1.25)   0.475   60/26    1.41(1.05-1.91)   0.025        
  Age (year)                                                                                                0.363
   ≤58         535/606          431/418   1.08(0.89-1.32)   0.431   109/54   1.48(1.22-1.79)   5.4 × 10−5   
   \>58        498/594          437/413   1.21(0.99-1.46)   0.055   88/65    1.19(0.99-1.43)   0.055        
  Smoking                                                                                                   0.096
   No          290/721          196/499   0.98(0.79-1.22)   0.863   42/68    1.27(1.03-1.56)   0.027        
   Yes         743/479          672/332   1.27(1.07-1.52)   0.008   155/51   1.36(1.14-1.61)   0.001        
  Drinking                                                                                                  0.980
   No          465/709          373/507   1.06(0.87-1.29)   0.582   85/63    1.44(1.19-1.74)   1.6 × 10−4   
   Yes         568/491          495/324   1.27(1.05-1.54)   0.013   112/56   1.24(1.04-1.48)   0.017        

  Variable          rs2736100 T\>G   *P*~interaction~^3^                                                                                
  ----------------- ---------------- --------------------- ----------------- -------------- --------- ------------------ -------------- -------
  Sex                                                                                                                                   0.253
   Male             478/610          750/762               1.25(1.06-1.47)   0.008          357/262   1.92(1.28-2.88)    0.002          
   Female           129/189          241/239               1.92(1.28-2.88)   0.002          141/85    1.77(1.40-2.24)    1.9 × 10^−6^   
  Age (year)                                                                                                                            0.606
   ≤58              311/411          502/497               1.27(1.02-1.57)   0.030          262/168   1.46(1.28-1.68)    6.1 × 10^−8^   
   \>58             296/388          489/504               1.36(1.10-1.68)   0.005          236/179   1.39(1.22-1.59)    1.2 × 10^−6^   
  Smoking status                                                                                                                        0.065
   No               138/479          244/600               1.48(1.15-1.89)   0.002          145/206   1.57(1.36-1.82)    1.4 × 10^−9^   
   Yes              469/320          747/401               1.27(1.05-1.54)   0.015          353/141   1.28(1.13-1.45)    8.3 × 10^−5^   
  Drinking status                                                                                                                       0.012
   No               221/486          463/588               1.90(1.52-2.37)   1.9 × 10^−6^   238/203   1.62 (1.41-1.85)   2.6 × 10^−8^   
   Yes              386/313          528/413               1.00(0.81-1.22)   0.974          260/144   1.22(1.07-1.39)    0.003          

  Variable     rs451360 G\>T   *P*~interaction~[^3^](#tfn_007){ref-type="table-fn"}                                                                      
  ------------ --------------- ------------------------------------------------------ ----------------- -------------- ------- ----------------- ------- -------
  Sex                                                                                                                                                    0.085
   Male        1305/1230       271/375                                                0.65(0.54-0.78)   3.6 × 10^−6^   11/30   0.60(0.42-0.86)   0.006   
   Female      423/416         85/92                                                  0.80(0.52-1.24)   0.326          3/7     0.63(0.26-1.54)   0.310   
  Age (year)                                                                                                                                             0.895
   ≤58         881/822         187/233                                                0.71(0.56-0.90)   0.005          7/23    0.57(0.36-0.90)   0.016   
   \>58        847/824         169/234                                                0.63(0.50-0.80)   1.3 × 10^−4^   7/14    0.66(0.41-1.06)   0.087   
  Smoking                                                                                                                                                0.932
   No          443/1001        82/263                                                 0.69(0.52-0.90)   0.007          3/24    0.50(0.27-0.91)   0.025   
   Yes         1285/645        274/204                                                0.69(0.56-0.85)   4.4 × 10^−4^   11/13   0.67(0.44-1.01)   0.057   
  Drinking                                                                                                                                               0.374
   No          777/1004        139/258                                                0.70(0.55-0.90)   0.006          7/17    0.74(0.46-1.20)   0.224   
   Yes         951/642         217/209                                                0.69(0.55-0.86)   0.001          7/20    0.53(0.34-0.82)   0.005   

Note: ESCC, esophageal squamous cell carcinoma; OR, odds ratio; CI, confidence interval.

Number of case patients with genotype/number of control subjects with genotype.

Data were calculated by logistic regression, adjusted for sex, age, smoking, and drinking status, where it was appropriate.

*P* values for gene-environment interaction were calculated using the multiplicative interaction term in SPSS software.

Functional relevance of TERT rs2736100 and CLPTM1L rs451360 genetic variants on gene expression {#s2_4}
-----------------------------------------------------------------------------------------------

Considering the chromosome location of the three ESCC susceptibility SNPs, we only investigated the impacts of *TERT* rs2736100 and *CLPTM1L* rs451360 SNPs on gene expression. The rs2736100 variant locates in the intron 2 region of *TERT*. As shown in Figure [1A](#F1){ref-type="fig"}, reporter gene assays demonstrated that the intron 2 segment containing the rs2736100 flanking sequence showed promoter activities in KYSE30 and KYSE150 ESCC cells. Moreover, the *TERT* rs2736100G allelic reporter construct (pTERT-G) showed significantly higher luciferase activities compared to the rs920778T allelic reporter construct (pTERT-T) (both *P*\<0.01) (Figure [1A](#F1){ref-type="fig"}). We next examined whether the ESCC susceptibility SNP rs451360 has an allele-specific effect on the intronic enhancer activity on *CLPTM1L* expression in ESCC. Either KYSE30 cells or KYSE150 cells transfected with the *CLPTM1L* pCL-T allelic plasmid showed significantly lower luciferase activities compared to cells expressing pCL-G allelic reporter construct (both *P*\<0.05) (Figure [1B](#F1){ref-type="fig"}).

![Transient luciferase reporter gene expression assays with constructs containing different rs2736100 allele of the TERT intron 2 region (A) or different rs451360 allele of the CLPTM1L intron 16 region (B) in KYSE30 cells or KYSE150 cells\
pRL-SV40 were cotransfected with these contructs to standardize transfection efficiency. Fold-changes were detected by defining the luciferase activity of cells co-transfected with pGL3-basic as 1. All experiments were performed in triplicates in three independent transfection experiments and each value represents mean ± SD. Compared with pGL3-Basic transfected cells, \**P*\<0.05; \*\**P*\<0.01.](oncotarget-07-5495-g001){#F1}

We next examined whether these two ESCC susceptibility SNPs has an allele-specific effect on gene expression in esophagus tissues. As shown in Figure [2A](#F2){ref-type="fig"}, we found that subjects with the rs920778 TT genotype had significantly lower *TERT* mRNA levels (mean ± SE) than those with the GG genotypes in normal esophagus tissues (0.128 ± 0.047 \[*n*=18\] vs. 0.493 ± 0.078 \[*n*=17\], *P*\<0.01) or ESCC tissues (0.030 ± 0.006 \[*n*=18\] vs. 0.847 ± 0.120 \[*n*=17\], *P*\<0.01). Similar results were observed when the *CLPTM1L* mRNA levels were compared between rs451360 GT+TT and GG genotypes in both normal tissues (0.713 ± 0.266 \[*n*=17\] vs. 4.810 ± 0.810 \[*n*=49\], *P*\<0.01) and ESCC specimens (1.059 ± 0.346 \[*n*=17\] vs. 10.650 ± 1.922 \[*n*=49\], *P*\<0.01).

![TERT or CLPTM1L mRNA expression in normal and cancerous esophageal tissues grouped by rs2736100 or rs451360 genotypes\
The expression of individual *TERT* or *CLPTM1L* mRNA was calculated relative to expression of *β-actin* using the 2^−dCt^ method. \*\**P*\<0.01.](oncotarget-07-5495-g002){#F2}

DISCUSSION {#s3}
==========

In the current study, we systematically examined the impacts of SNPs in the *TERT-CLPTM1L* loci on ESCC susceptibility via a case-control design as well as gene expression of *TERT* or *CLPTM1L in vitro* and *in vivo*. After genotyping 15 htSNPs in the discovery stage, we identified three ESCC susceptibility genetic polymorphisms (rs2853691, rs2736100 and rs451360) which were validated in two validation case-control sets. Reporter gene assays indicated that the ESCC susceptibility SNP rs2736100 locating in a potential *TERT* intronic promoter has a genotype-specific effect on *TERT* expression. Similarly, the *CLPTM1L* rs451360 polymorphism also showed allelic effects on gene expression. Genotype-phenotype correlation data supported the regulatory role of these two genetic variants in *TERT* or *CLPTM1L* gene expression *in vivo*. Our observations support the hypothesis that genetic polymorphisms in oncogene regulatory elements might explain a part of ESCC genetic basis besides those genetic variants identified by GWAS \[[@R27]--[@R31]\].

Interestingly, *TERT* rs2736100 has been found to be associated with risk of lung cancer \[[@R1],[@R2],[@R24]\], glioma\[[@R9]\], testicular cancer \[[@R12]\],colorectal cancer \[[@R33]\], acute myeloid leukemia \[[@R34]\], pancreatic cancer \[[@R35]\] and bladder cancer \[[@R36]\]. However, its involvement in ESCC etiology is still largely unclear. To the best of our knowledge, this is the first case-control study to investigate the association between the *TERT* rs2736100 polymorphism and ESCC risk. We observed a significantly increased ESCC risk among individuals with *TERT* rs2736100 G allele compared to carriers of rs2736100 T allele. It has been reported that increased TERT expression in ESCC tissues were observed compared to normal tissues \[[@R18],[@R19]\], which indicated the oncogene nature of *TERT* in ESCC. Since rs2736100 G allele is associated with elevated *TERT* expression, the associations between the polymorphism and increased cancer risk are biologically plausible.

*CLPTM1L* appears to act as an oncogene with significantly increased expression in malignant tissues \[[@R20]--[@R23]\]. In line with this, CLPTM1L silencing by miR-494 can inhibit cell growth and invasion and induce ESCC cell apoptosis \[[@R23]\]. The *CLPTM1L* rs451360 polymorphism has been associated with decreased risk of lung cancer among different ethnic populations, with T allele as a protective allele \[[@R5],[@R37]-[@R41]\]. Here, we provided first evidences that rs451360 SNP also play a part in ESCC susceptibility, which are unlikely to be attributable to unknown confounding factors due to having relatively large sample sizes, significantly increased odd ratios with small *P* values. Additionally, our genotype-phenotype correlation data between the rs451360 genetic variant and gene expression supports the case-control study since the protective T allele carriers showing less oncogene *CLPTM1L* expression. Since the TT genotype of the functional rs451360 SNP is relatively rare (about 1-2% among common populations), the potential clinical translation of this genetic variant might be compromised.

In conclusion, we demonstrated that there are three genetic polymorphisms (rs2853691, rs2736100 and rs451360) in the *TERT-CLPTM1L* loci are significantly associated with ESCC risk in Chinese populations. Our results underline the complexity of genetic regulation of telomere biology and further support the important role of telomerase in carcinogenesis. Our data also support the involvement of *CLPTM1L* in ESCC susceptibility. These results may lead to better understanding of ESCC etiology in different populations.

MATERIALS AND METHODS {#s4}
=====================

Study subjects {#s4_1}
--------------

This study consisted of three case-control sets: (a) Jiangsu set: 588 ESCC cases from Huaian No. 2 Hospital (Huaian, Jiangsu Province, China) and sex- and age-matched 600 controls. (b) Shandong set: 1000 cases with ESCC from Shandong Cancer Hospital, Shandong Academy of Medical Sciences (Jinan, Shandong Province, China) and sex- and age-matched (± 5 years) 1000 healthy controls. (c) Hebei study: 510 ESCC patients from Bethune International Peace Hospital (Shijiazhuang, Hebei Province, China) and 550 sex- and age-matched healthy controls. Sixty-six pairs of ESCC specimens and esophagus normal tissues adjacent to the tumors were obtained from surgically removed specimens of patients in Bethune International Peace Hospital and Huaian No. 2 Hospital. All individuals were ethnic Han Chinese. At recruitment, the informed consent was obtained from each subject. The detailed information on subject recruitments can be found in [Supplementary Table S1](#SD1){ref-type="supplementary-material"} and our previous studies \[[@R42]--[@R44]\]. This study was approved by the institutional Review Boards.

SNP selection and genotyping {#s4_2}
----------------------------

The *TERT-CLPTM1L* gene loci cover a 91716bp region of chromosome 5p15.33 and contain a great number of SNPs. An htSNP approach was utilized to analyze the *TERT-CLPTM1L* genetic polymorphisms globally \[[@R45]\]. Genotyped HapMap SNPs among Han Chinese and Japanese populations (HapMap Rel 21, NCBI B36) with a minor allele frequency \>5% were included in the selection. The htSNPs were chosen in a 95716bp region (91716bp *TERT-CLPTM1L* loci and 2kb up-stream as well as 2kb down-stream regions of the *TERT-CLPTM1L* gene loci). Using a method described previously with the sample size inflation factor, Rh^2^, of ≥ 0.8, fifteen htSNPs were selected with Haploview 4.2 software on a block-by-block basis ([Supplementary Table S2](#SD1){ref-type="supplementary-material"}).

*TERT-CLPTM1L* htSNPs were genotyped through the MassArray system (Sequenom Inc., San Diego, California, USA). A 5% blind, random DNA samples was analyzed in duplicates and the reproducibility was 99%. To reduce the costs of the study, we genotyped the *TERT-CLPTM1L* rs2853691 A\>G, rs2736100 T\>G and rs451360 G\>T SNPs in two validation sets using the PCR-based restriction fragment length polymorphism (RFLP) as described in [Supplementary Table S3](#SD1){ref-type="supplementary-material"}. A 5% samples were genotyped by two investigators and the reproducibility was 98.0%.

Luciferase reporter gene constructs {#s4_3}
-----------------------------------

Specific primer pairs ([Supplementary Table S4](#SD1){ref-type="supplementary-material"}) with the *Kpn*I and *Xho*I restriction sites were used to amplify the intron 2 segment of *TERT* (chr.5: 1319429∼1319865 bp \[GRCh38.p2\] including the rs2736100 flanking region) from human genomic DNA carrying *TERT* rs2736100 TT genotype or GG genotype. Similarly, the intron 16 segment of *CLPTM1L* (chr.5: 1285954∼1286844 bp \[GRCh38.p2\] including the rs451360 flanking region) was amplified with human genomic DNA carrying *CLPTM1L* rs451360 GG genotype or TT genotype. The PCR products were then digested with *Kpn*I and *Xho*I (New England Biolabs) and ligated into an appropriately digested pGL3-Basic vector (*TERT*) or pGL3-Promoter vector (*CLPTM1L*). The resultant *TERT* reporter gene plasmids were designated pTERT-T or pTERT-G, which were only different at rs2736100 polymorphic site. The resultant *CLPTM1L* reporter gene plasmids were named as pCL-T or pCL-G, which were identical except for the different allele at rs451360 polymorphic site. Restriction analysis and complete DNA sequencing confirmed the orientation and integrity of these constructs.

Dual luciferase reporter assays {#s4_4}
-------------------------------

KYSE30 and KYSE150 ESCC cells were transfected with both reporter constructs (pGL3-Basic, pTERT-T, pTERT-G, pGL3-Promoter, pCL-T or pCL-G) and pRL-SV40 (Luciferase Assay System; Promega). Dual luciferase activities were determined at 48h after transfection as previously described \[[@R46],[@R47]\]. For each plasmid construct, three independent transfection experiments were performed, and each was done in triplicates.

Real-time analysis of TERT and CLPTM1L mRNA {#s4_5}
-------------------------------------------

Total cellular RNA was isolated from sixty-six pairs of ESCC specimens and esophagus normal tissues adjacent to the tumors with TRIzol Reagent (Invitrogen) and converted to cDNA using the PrimeScript RT Master Mix (TAKARA). *TERT* and *CLPTM1L* mRNA expression in cancerous and normal esophagus tissues was examined using the TaqMan real-time quantity PCR method. Relative gene expression quantization for *TERT* (ABI, Assay ID Hs00972656_m1) and *CLPTM1L* (ABI, Assay ID Hs00363947_m1) was calculated using *β-actin* (ABI, Assay ID 4333762T) as an internal reference gene was carried out using the ABI 7500 real-time PCR system in triplicates.

Statistics {#s4_6}
----------

Pearson\'s χ^2^ test was used to examine the differences in demographic variables, smoking status, drinking status, and genotype distributions of rs2853691, rs2736100 or rs451360 SNP between ESCC cases and healthy controls. The associations between rs2853691, rs2736100 or rs451360 genotypes and ESCC risk were estimated by odds ratios and their 95% confidence intervals computed by logistic regression models. All ORs were adjusted for age, sex, smoking or drinking status, where it was appropriate. A *P* value of less than 0.05 was used as the criterion of statistical significance, and all statistical tests were two-sided. All analyses were performed using SPSS 16.0 (SPSS Inc.).
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